BIO-TECHNE DECLARES DIVIDEND
Bio-Techne (NASDAQ: TECH) has announced a quarterly dividend of $0.08 per share for the quarter ended June 30, 2025. The dividend will be payable on August 29, 2025, to shareholders of record as of August 18, 2025.
The company, a global life sciences leader providing innovative tools and bioactive reagents for research and clinical diagnostics, reported net sales of $1.2 billion in fiscal 2025 and employs approximately 3,100 people worldwide. Bio-Techne's products support scientific research into biological processes, disease progression, drug discovery, and clinical diagnostics.
Bio-Techne (NASDAQ: TECH) ha annunciato un dividendo trimestrale di 0,08 $ per azione relativo al trimestre terminato il 30 giugno 2025. Il dividendo sar脿 pagabile il 29 agosto 2025 agli azionisti registrati al 18 agosto 2025.
L'azienda, leader mondiale nelle scienze della vita che offre strumenti innovativi e reagenti bioattivi per la ricerca e la diagnostica clinica, ha riportato vendite nette per 1,2 miliardi di dollari nell'anno fiscale 2025 e impiega circa 3.100 persone in tutto il mondo. I prodotti di Bio-Techne supportano la ricerca scientifica sui processi biologici, la progressione delle malattie, la scoperta di farmaci e la diagnostica clinica.
Bio-Techne (NASDAQ: TECH) ha anunciado un dividendo trimestral de 0,08 $ por acci贸n para el trimestre finalizado el 30 de junio de 2025. El dividendo se pagar谩 el 29 de agosto de 2025 a los accionistas registrados a fecha del 18 de agosto de 2025.
La compa帽铆a, l铆der global en ciencias de la vida que ofrece herramientas innovadoras y reactivos bioactivos para la investigaci贸n y el diagn贸stico cl铆nico, report贸 ventas netas de 1.200 millones de d贸lares en el a帽o fiscal 2025 y cuenta con aproximadamente 3,100 empleados en todo el mundo. Los productos de Bio-Techne apoyan la investigaci贸n cient铆fica sobre procesos biol贸gicos, progresi贸n de enfermedades, descubrimiento de f谩rmacos y diagn贸stico cl铆nico.
Bio-Techne (NASDAQ: TECH)電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴鞐� 雽�頃� 欤茧嫻 0.08雼煬鞚� 攵勱赴 氚半嫻旮堨潉 氚滍憸頄堨姷雼堧嫟. 氚半嫻旮堨潃 2025雲� 8鞗� 29鞚�鞐� 歆�旮夒悩氅�, 2025雲� 8鞗� 18鞚� 旮办 欤检＜鞐愱矊 歆�旮夒惄雼堧嫟.
鞚� 須岇偓電� 順侅嫚鞝侅澑 鞐瓣惮 霃勱惮鞕� 靸濎泊 頇滌劚 鞁滌暯鞚� 鞝滉车頃橂姅 旮�搿滊矊 靸濍獏瓿柬暀 靹犽憪 旮办梾鞙茧, 2025 須岅硠鞐半弰鞐� 12鞏� 雼煬鞚� 靾滊Г於�鞚� 旮半頄堨溂氅� 鞝� 靹戈硠 鞎� 3,100氇呾潉 瓿犾毄頃橁碃 鞛堨姷雼堧嫟. Bio-Techne鞚� 鞝滍拡鞚� 靸濍頃欖爜 瓿检爼, 歆堧硲 歆勴枆, 鞁犾暯 臧滊皽 氚� 鞛勳儊 歆勲嫧鞐� 雽�頃� 瓿柬暀鞝� 鞐瓣惮毳� 歆�鞗愴暕雼堧嫟.
Bio-Techne (NASDAQ : TECH) a annonc茅 un dividende trimestriel de 0,08 $ par action pour le trimestre clos le 30 juin 2025. Le dividende sera vers茅 le 29 ao没t 2025 aux actionnaires inscrits au registre au 18 ao没t 2025.
L'entreprise, leader mondial des sciences de la vie fournissant des outils innovants et des r茅actifs bioactifs pour la recherche et le diagnostic clinique, a d茅clar茅 un chiffre d'affaires net de 1,2 milliard de dollars pour l'exercice 2025 et emploie environ 3 100 personnes dans le monde. Les produits de Bio-Techne soutiennent la recherche scientifique sur les processus biologiques, la progression des maladies, la d茅couverte de m茅dicaments et le diagnostic clinique.
Bio-Techne (NASDAQ: TECH) hat eine viertelj盲hrliche Dividende von 0,08 $ pro Aktie f眉r das Quartal zum 30. Juni 2025 angek眉ndigt. Die Dividende wird am 29. August 2025 an die Aktion盲re ausgezahlt, die am 18. August 2025 im Register stehen.
Das Unternehmen, ein weltweit f眉hrendes Life-Science-Unternehmen, das innovative Werkzeuge und bioaktive Reagenzien f眉r Forschung und klinische Diagnostik bereitstellt, meldete im Gesch盲ftsjahr 2025 einen Nettoumsatz von 1,2 Milliarden US-Dollar und besch盲ftigt weltweit etwa 3.100 Mitarbeiter. Die Produkte von Bio-Techne unterst眉tzen die wissenschaftliche Forschung zu biologischen Prozessen, Krankheitsverl盲ufen, Wirkstoffentdeckung und klinischer Diagnostik.
- Generated significant revenue of $1.2 billion in fiscal 2025
- Maintains consistent shareholder returns through quarterly dividend program
- Strong market presence with thousands of products in portfolio
- Relatively small dividend amount of $0.08 per share
- Faces increasing competition in biotechnology research products market
- Subject to currency exchange rate fluctuation risks
叠颈辞-罢别肠丑苍别听颁辞谤辫辞谤补迟颈辞苍听(狈础厂顿础蚕:听TECH)聽is聽a聽global聽life聽sciences company聽providing聽innovative tools聽and聽bioactive reagents聽for聽the聽research and聽clinical聽diagnostic聽communities.聽Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately
Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.
For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.
Contact:聽 聽 | David Clair, Vice President, Investor Relations & Corporate Development |
612-656-4416 |
View original content to download multimedia:
SOURCE Bio-Techne Corporation
FAQ
What is Bio-Techne's (NASDAQ: TECH) latest dividend amount and payment date?
How much revenue did Bio-Techne generate in fiscal 2025?
How many employees does Bio-Techne have globally?
What are the main business areas of Bio-Techne (NASDAQ: TECH)?
When is the record date for Bio-Techne's latest dividend?
